Further studies are needed with RNA interference (RNAi) or small interfering RNA (siRNA) and additional β-adrenergic agonists and antagonists to further determine the effects of GIRK1 and GIRK2 on β-adrenergic signaling in human lung cancer, especially studies on differences in GIRK protein expression. The gene discussed is KCNJ3; the disease is lung cancer.